Zobrazeno 1 - 10
of 122
pro vyhledávání: '"Wlodzimierz Buczko"'
Autor:
Barbara Mroczko, Anna Tankiewicz-Kwedlo, Dariusz Pawlak, Irena Kasacka, Iwona Kucharewicz, Wlodzimierz Buczko, Anna Bodzenta-Lukaszyk
Publikováno v:
Folia Histochemica et Cytobiologica, Vol 46, Iss 2, Pp 199-203 (2008)
Asthma is a chronic inflammatory disease that involves the immune system activation. Evidence is accumulating about the role of kynurenine pathway in the immune system regulation. The kynurenine pathway includes several metabolites of tryptophan, amo
Externí odkaz:
https://doaj.org/article/24491f7fc31f42a0bebde6b0bcf514db
Autor:
Wlodzimierz Buczko, Agnieszka Leszczynska, Barbara Sitek, Ewa Chabielska, R. T. Smolenski, Tomasz W. Kaminski, Karol Kramkowski, Bartosz Proniewski, U. Rykaczewska, Agnieszka Zakrzewska, Kamil Przyborowski, Stefan Chlopicki
Publikováno v:
Platelets. 27:245-253
The mechanisms underlying nitrite-induced effects on thrombosis and hemostasis in vivo are not clear. The goal of the work described here was to investigate the role of xanthine oxidoreductase (XOR) in the anti-platelet and anti-thrombotic activities
Publikováno v:
Pharmacological Reports. 67:695-703
Fibrinolysis is an action of converting plasminogen by its activators, like tissue- or urokinase-type plasminogen activators (t-PA, u-PA), to plasmin, which in turn cleaves fibrin, thereby causing clot dissolution and restoration of blood flow. Endot
Autor:
Piotr Buczko, Anna Tankiewicz-Kwedlo, Wlodzimierz Buczko, Justyna Magdalena Hermanowicz, Adam Hermanowicz
Publikováno v:
Pharmacological Reports. 67:173-178
Background Aliskiren is the first orally active inhibitor of renin to be approved for clinical use as an antihypertensive agent. A number of studies show a link between aliskiren and intravascular thrombosis. Materials and methods The goal of the pre
Autor:
Elżbieta Grochal, Tomasz Brzoska, Brian E. Mann, Tetsumei Urano, Wlodzimierz Buczko, Andrzej Mogielnicki, Andrzej Fedorowicz, Agnieszka Leszczynska, Roberto Motterlini, Karol Kramkowski, Stefan Chlopicki
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology
Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association, 2012, 32 (9), pp.2149-57. ⟨10.1161/ATVBAHA.112.253989⟩
Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association, 2012, 32 (9), pp.2149-57. ⟨10.1161/ATVBAHA.112.253989⟩
Objective— We compared the antithrombotic effects in vivo of 2 chemically different carbon monoxide–releasing molecules (CORM-A1 and CORM-3) on arterial and venous thrombus formation and on hemostatic parameters such as platelet activation, coagu
Autor:
Stefan Chlopicki, Roberto Motterlini, Andrzej Fedorowicz, Magdalena Lomnicka, Andrzej Mogielnicki, Elżbieta Grochal, Wlodzimierz Buczko, Karol Kramkowski
Publikováno v:
Naunyn-Schmiedeberg's Archives of Pharmacology
Carbon monoxide (CO) and CO-releasing molecules (CO-RMs) inhibit platelet aggregation in vitro. Herein, we compare the anti-platelet action of CORM-3, which releases CO rapidly (t (½) 1 min), and CORM-A1, which slowly releases CO (t(½) = 21 min). T
Publikováno v:
Advances in Medical Sciences. 56:123-131
Periodontal disease is mainly associated with the activity of bacteria which adhere to the tooth surface and form specific structure of bacterial biofilm. Periodontal bacteria cause inflammation of the gums and aggressive immune response, affecting t
Publikováno v:
Pharmacological Reports. 62:926-937
Supplementation of recombinant human erythropoietin (rHuEpo) is one of the methods for the treatment of anemia. The influence of rHuEpo on proliferation or clonogenic growth of cancer cells is not clear and some of the published results are conflicti
Publikováno v:
Polish Annals of Medicine. 17:16-24
Introduction. Supplementation of recombinant human erythropoietin (rHuEpo) is one of the methods for the treatment of anemia for patients with colon cancer. However, the results of in vitro studies investigating the influence of rHuEpo on cancer cell
Publikováno v:
Scandinavian Journal of Haematology. 34:146-151
Platelets of patients with myeloproliferative disorders (MD) such as polycythaemia vera (PV), chronic myelogenous leukaemia (CML), idiopathic myelofibrosis (IM) and essential thrombocythaemia (ET) have been found to have low 5HT levels measured both